Learn how we’re helping manufacturers adopt the latest technologies to make breakthrough therapeutics available to all
Despite incredible therapeutic innovations, the process for manufacturing these life-changing drugs lagged behind.
Because of the largely paper-based processes involved in pharma manufacturing, millions of dollars were lost in drug batches due to quality deviations. These legacy processes just weren’t going to hold up to the demands of new therapies – biologics, cell, and gene.
We created Apprentice to bring the pharma industry up to speed with the transformative potential of technology.
By bringing together co-founder Angelo Stracquantanio from the world of tech with fellow co-founders Gary Pignata and Alexandra Buttke from pharma, we’re developing expeditious ways to create medicines that will forever make life better for the people who need them most – patients.
Co-founders met and identified how modern technology could solve the inefficiencies in the drug production process.
First customers successfully used our web portal and wearable headset to connect remote colleagues to the manufacturing suite and we raised a $2.5 million seed round.
Raised an $8 million Series A round to meet the demands of a growing, global customer base and expand product capabilities.
The COVID-19 pandemic hit and we helped our customers keep drug production going, leading to a $24 million Series B round to keep pace with exploding customer demand.
We launched our vision for one platform to turn molecules into medicine.
We’re backed on this journey by leading investors in tech and healthcare. Together, we’re invested in helping the industry transform.
We’re building a company for the future led by innovators from high-growth tech and pharma.
Fill out this form to start a conversation with an Apprentice team member and get your questions answered.
